Sonidegib potentiates the cancer cells’ sensitivity to cytostatic agents by functional inhibition of ABCB1 and ABCG2 in vitro and ex vivo

[Display omitted] Sonidegib (LDE-225) is a Hedgehog pathway inhibitor used for the therapy of basal cell carcinoma. In addition, the drug is a subject of clinical trials for the treatment of other solid tumors including non-small cell lung cancer (NSCLC). In this study, we explored the potential of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biochemical pharmacology 2022-05, Vol.199, p.115009-115009, Article 115009
Hauptverfasser:	Zhang, Yu, Vagiannis, Dimitrios, Budagaga, Youssif, Sabet, Ziba, Hanke, Ivo, Rozkoš, Tomáš, Hofman, Jakub
Format:	Artikel
Sprache:	eng
Schlagworte:	ABC transporter Antineoplastic Agents - pharmacology ATP Binding Cassette Transporter, Subfamily B - genetics ATP Binding Cassette Transporter, Subfamily G, Member 2 - metabolism Biphenyl Compounds Carcinoma, Non-Small-Cell Lung - drug therapy Cell Line, Tumor Cytochrome P450 Cytostatic Agents - pharmacology Drug Resistance, Neoplasm Hedgehog Proteins - metabolism Humans Lung Neoplasms - drug therapy Neoplasm Proteins - metabolism Non-small cell lung cancer Pharmacokinetic resistance Pyridines Sonidegib
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!